Fast Facts About Anika Therapeutics, Inc.
President & CEO: |
Charles H. Sherwood, Ph.D.
|
Founded: |
1993 |
2008 Revenue: |
$35.8 million |
2008 R & D Spending: |
$7.4 million (21% of total revenue) |
Employees: |
84 as of December 31, 2008 |
Headquarters: |
Bedford, MA |
Exchange and Symbol: |
NASDAQ Global Select Market ® under the symbol: ANIK |
Areas of Focus: |
Joint Health Relief of pain due to osteoarthritis Aesthetics Dermal fillers to reduce wrinkles Ophthalmic Viscoelastic used in connection with intraocular surgery Veterinary Relief of pain due to osteoarthritis Anti-Adhesion Prevention of post-surgical adhesions |
Top Products, based on 2008 Revenue: |
||
Product Name |
Disease/Condition |
2008 Revenue |
ORTHOVISC® |
Osteoarthritis |
$18.7 million |
AMVISC®, AMVISC® Plus |
Intraocular surgery |
$10.7 million |
HYVISC® |
Equine osteoarthritis |
$3 million |
Key Pipeline Products: |
|
Product Name |
Disease/Condition |
MONOVISC™ |
Osteoarthritis, U.S. clinical trials underway, launched in Europe |
CINGAL™ |
Osteoarthritis, pre-clinical development |
ELEVESS™ Line Extension |
Aesthetic dermatology |
